I'll post it for youWeedMD Inc. Notes to the Amended and Restated Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Unaudited – Expressed in Canadian Dollars) 30 21. Subsequent events The Company’s management has evaluated subsequent events up to February 26, 2021, the date the consolidated financial statements were issued and determined the following events: a) On February 11, 2021, the Company announced it has entered into a letter of engagement with Eight Capital, under which Eight capital has agreed to purchase, as joint bookrunner and co-lead underwriter along with Canaccord Genuity Corp., 21,342,000 units of the Company (the “Units”), on a bought deal basis at a price per Unit of $0.82 for gross proceeds of $17,500,440. Each Unit will be comprised of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, “Warrant”). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $1.00, for a period of 24 months following the closing of the Offering. If, after the one-year anniversary of the closing of the Offering, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange for any 10 consecutive days equals or exceeds $1.64, the Company may, upon providing written notice to the holders of the Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice. The closing of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals of the applicable securities regulatory authorities. b) On February 10, 2021, one consultant has exercised the option for 425,000 shares. c) On January 7, 2021, the Company exited the Bowmanville facility and reallocated all medical packaging, labelling and distribution activities from its Bowmanville, Ontario site to its Aylmer, Ontario facility.